Recent News

• 12.12.2025 - BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
• 12.04.2025 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.03.2025 - BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Recent Filings

• 12.12.2025 - EX-99.1 EX-99.1
• 12.12.2025 - 8-K Current report
• 12.11.2025 - 8-K Current report
• 12.03.2025 - 8-K Current report
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 144 Report of proposed sale of securities
• 12.03.2025 - 425 Prospectuses and communications, business combinations
• 12.03.2025 - EX-99.1 EX-99.1
• 12.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.02.2025 - 4 Statement of changes in beneficial ownership of securities